{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:31:49Z","timestamp":1793457109379,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hypothalamic obesity (HO) is a treatment-related complication in craniopharyngioma (CP) survivors that markedly impairs long-term health and quality of life. Although overall survival exceeds 90% for both pediatric and adult CP, HO prevalence and clinical course differ substantially by age at onset. We aimed to compare HO manifestations, mechanisms, and treatment response between pediatric and adult CP cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a scoping review of studies published between 2000 and 2025, comparing pediatric (childhood-onset) versus adult-onset CP cohorts, classified by age at diagnosis. Data on obesity prevalence, mechanistic pathways, therapeutic interventions, and cardiometabolic outcomes were extracted and synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In pediatric CP survivors, obesity rates rise from 5.7% pre-treatment to 57% post-treatment; in adults, from 19.2% to 29.2%. HO severity correlates with the extent of hypothalamic damage by Puget and QST grading. Key mechanisms include disrupted melanocortin signaling, central leptin and insulin resistance, and neuroinflammation via resistin\u2013TLR4 and NLRP3 pathways. GLP-1 receptor agonists (exenatide, semaglutide) have produced marked weight loss in small case series (up to 17% over 6 months with semaglutide), but randomized trials did not meet their primary weight outcomes and direct pediatric-versus-adult comparisons are lacking. Bariatric procedures yield moderate success; sleeve gastrectomy achieves 5-year weight loss comparable to that in non-CP controls (21.7% vs. 21.8%), whereas Roux-en-Y gastric bypass is less effective than in controls (22.7% vs. 32.0%). Both cohorts face significant long-term risks: 2.2-fold higher all-cause mortality and 9.3-fold higher diabetes risk in adults, non-alcoholic fatty liver disease in 47% of pediatric survivors, metabolic dysfunction-associated fatty liver disease in 67.4% of adults, and insulin resistance in approximately 30% of pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HO following CP shows distinct age-dependent trajectories in prevalence, underlying mechanisms, and clinical course; suggested age-related differences in treatment response remain to be confirmed in direct comparative studies. Tailored management integrating mechanistic insights and age-specific therapies is critical to mitigating the cardiometabolic burden in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01760-z","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:08:31Z","timestamp":1790514511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes"],"prefix":"10.1007","volume":"29","author":[{"given":"Khushal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Zeinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Altschul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"7","key":"1760_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","volume":"17","author":"AS Sterkenburg","year":"2015","unstructured":"Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenb\u00fcchel AMM, M\u00fcller HL (2015) Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol 17(7):1029\u20131038. https:\/\/doi.org\/10.1093\/neuonc\/nov044","journal-title":"Neuro Oncol"},{"key":"1760_CR2","doi-asserted-by":"publisher","first-page":"876770","DOI":"10.3389\/fendo.2022.876770","volume":"13","author":"M Craven","year":"2022","unstructured":"Craven M, Crowley JH, Chiang L, Kline C, Malbari F, Hocking MC et al (2022) A survey of patient-relevant outcomes in pediatric craniopharyngioma: focus on hypothalamic obesity. Front Endocrinol 13:876770. https:\/\/doi.org\/10.3389\/fendo.2022.876770","journal-title":"Front Endocrinol"},{"key":"1760_CR3","doi-asserted-by":"publisher","first-page":"694213","DOI":"10.3389\/fendo.2021.694213","volume":"12","author":"W Wu","year":"2021","unstructured":"Wu W, Sun Q, Zhu X, Xiang B, Zhang Q, Miao Q et al (2021) Risk factors for hypothalamic obesity in patients with adult-onset craniopharyngioma: a consecutive series of 120 cases. Front Endocrinol 12:694213. https:\/\/doi.org\/10.3389\/fendo.2021.694213","journal-title":"Front Endocrinol"},{"issue":"3","key":"1760_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11060-013-1128-0","volume":"113","author":"SW Park","year":"2013","unstructured":"Park SW, Jung HW, Lee YA, Shin CH, Yang SW, Cheon JE (2013) Tumor origin and growth pattern at diagnosis and surgical hypothalamic damage predict obesity in pediatric craniopharyngioma. J Neuro Oncol 113(3):417\u2013424. https:\/\/doi.org\/10.1007\/s11060-013-1128-0","journal-title":"J Neuro Oncol"},{"key":"1760_CR5","doi-asserted-by":"publisher","first-page":"1256514","DOI":"10.3389\/fendo.2023.1256514","volume":"14","author":"CL Roth","year":"2023","unstructured":"Roth CL, Zenno A (2023) Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol 14:1256514. https:\/\/doi.org\/10.3389\/fendo.2023.1256514","journal-title":"Front Endocrinol"},{"issue":"1","key":"1760_CR6","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae200","volume":"9","author":"P Dimitri","year":"2025","unstructured":"Dimitri P, Roth CL (2025) Treatment of hypothalamic obesity with GLP-1 analogs. J Endocr Soc 9(1):bvae200. https:\/\/doi.org\/10.1210\/jendso\/bvae200","journal-title":"J Endocr Soc"},{"key":"1760_CR7","doi-asserted-by":"publisher","unstructured":"He M, Xu H, Ying Z, Chen Y, Li X (2024) Effectiveness of bariatric surgery on acquired hypothalamic obesity: a systematic review and meta-analysis. Endocr Connect 13(12). https:\/\/doi.org\/10.1530\/ec-24-0493","DOI":"10.1530\/ec-24-0493"},{"issue":"6","key":"1760_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061099","volume":"16","author":"J Beckhaus","year":"2024","unstructured":"Beckhaus J, Friedrich C, M\u00fcller HL (2024) Vascular morbidity and mortality in craniopharyngioma patients: a scoping review. Cancers (Basel) 16(6):1099. https:\/\/doi.org\/10.3390\/cancers16061099","journal-title":"Cancers (Basel)"},{"issue":"Supplement1","key":"1760_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1227\/neu.0000000000003360_333","volume":"71","author":"N Chapman","year":"2025","unstructured":"Chapman N, Shapiro J, Malone T, Krieger MD (2025) The Degree of Hypothalamic Involvement and Its Effects on BMI in Pediatric Craniopharyngioma. Neurosurgery 71(Supplement1):80. https:\/\/doi.org\/10.1227\/neu.0000000000003360_333","journal-title":"Neurosurgery"},{"issue":"1","key":"1760_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3171\/2019.8.peds19295","volume":"25","author":"R Whelan","year":"2019","unstructured":"Whelan R, Prince E, Mirsky DM, Naftel R, Bhatia A, Pettorini B et al (2019) Interrater reliability of a method to assess hypothalamic involvement in pediatric adamantinomatous craniopharyngioma. J Neurosurg Pediatr 25(1):37\u201342. https:\/\/doi.org\/10.3171\/2019.8.peds19295","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"1760_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ejendo\/lvad027","volume":"188","author":"J Beckhaus","year":"2023","unstructured":"Beckhaus J, Friedrich C, Boekhoff S, Calaminus G, Bison B, Eveslage M et al (2023) Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage. Eur J Endocrinol 188(3):300\u2013309. https:\/\/doi.org\/10.1093\/ejendo\/lvad027","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1760_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3171\/2023.5.peds22568","volume":"32","author":"OK Yousuf","year":"2023","unstructured":"Yousuf OK, Salehani A, Zimmerman K, Estevez-Ordonez D, Madura C, Arynchyna-Smith A et al (2023) Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study. J Neurosurg Pediatr 32(5):569\u2013575. https:\/\/doi.org\/10.3171\/2023.5.peds22568","journal-title":"J Neurosurg Pediatr"},{"issue":"Supplement1","key":"1760_CR13","doi-asserted-by":"publisher","first-page":"i143","DOI":"10.1093\/neuonc\/noac079.527","volume":"24","author":"E Hoving","year":"2022","unstructured":"Hoving E, van Baarsen K, van Schaik J, van Santen H (2022) SURG-09. Hypothalamic involvement in pediatric craniopharyngiomas; how to define and to realize optimal neurosurgical resections. Neuro Oncol 24(Supplement1):i143\u2013i144. https:\/\/doi.org\/10.1093\/neuonc\/noac079.527","journal-title":"Neuro Oncol"},{"key":"1760_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.25259\/sni_399_2024","volume":"15","author":"IWW Wisnawa","year":"2024","unstructured":"Wisnawa IWW, Haq IBI (2024) Comparative efficacy of transcranial and endoscopic surgery for craniopharyngioma: A systematic review and meta-analysis of contemporary literature. Surg Neurol Int 15:356. https:\/\/doi.org\/10.25259\/sni_399_2024","journal-title":"Surg Neurol Int"},{"key":"1760_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1058329","volume":"12","author":"MK Na","year":"2022","unstructured":"Na MK, Jang B, Choi KS, Lim TH, Kim W, Cho Y et al (2022) Craniopharyngioma resection by endoscopic endonasal approach versus transcranial approach: a systematic review and meta-analysis of comparative studies. Front Oncol 12:1058329. https:\/\/doi.org\/10.3389\/fonc.2022.1058329","journal-title":"Front Oncol"},{"key":"1760_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.755342","volume":"12","author":"C Nie","year":"2022","unstructured":"Nie C, Ye Y, Wu J, Zhao H, Jiang X, Wang H (2022) Clinical outcomes of transcranial and endoscopic endonasal surgery for craniopharyngiomas: a single-institution experience. Front Oncol 12:755342. https:\/\/doi.org\/10.3389\/fonc.2022.755342","journal-title":"Front Oncol"},{"issue":"1","key":"1760_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12957-024-03411-8","volume":"22","author":"S Li","year":"2024","unstructured":"Li S, Ye Y, Nie C, Huang X, Yan K, Zhang F (2024) Endoscopic endonasal transsphenoidal approach improves endocrine function and surgical outcome in primary craniopharyngioma resection: a systematic review and meta-analysis. World J Surg Oncol 22(1):137. https:\/\/doi.org\/10.1186\/s12957-024-03411-8","journal-title":"World J Surg Oncol"},{"issue":"14","key":"1760_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.21037\/atm-21-2924","volume":"9","author":"W Hu","year":"2021","unstructured":"Hu W, Qiu B, Mei F, Mao J, Zhou L, Liu F (2021) Clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study. Ann Transl Med 9(14):1164. https:\/\/doi.org\/10.21037\/atm-21-2924","journal-title":"Ann Transl Med"},{"issue":"1","key":"1760_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28282-4","volume":"8","author":"B Tang","year":"2018","unstructured":"Tang B, Xie SH, Xiao LM, Huang GL, Wang ZG, Yang L (2018) A novel endoscopic classification for craniopharyngioma based on its origin. Sci Rep 8(1):10215. https:\/\/doi.org\/10.1038\/s41598-018-28282-4","journal-title":"Sci Rep"},{"issue":"9","key":"1760_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnen\/nlaa087","volume":"79","author":"S Qi","year":"2020","unstructured":"Qi S, Liu Y, Wang C, Fan J, Pan J, Zhang X (2020) Membrane Structures Between Craniopharyngioma and the Third Ventricle Floor Based on the QST Classification and Its Significance: A Pathological Study. J Neuropathol Exp Neurol 79(9):966\u2013974. https:\/\/doi.org\/10.1093\/jnen\/nlaa087","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"1760_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3171\/2015.7.peds14449","volume":"17","author":"J Pan","year":"2016","unstructured":"Pan J, Qi S, Liu Y, Lu Y, Peng J, Zhang X (2016) Growth patterns of craniopharyngiomas: clinical analysis of 226 patients. J Neurosurg Pediatr 17(4):418\u2013433. https:\/\/doi.org\/10.3171\/2015.7.peds14449","journal-title":"J Neurosurg Pediatr"},{"issue":"8","key":"1760_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1210\/clinem\/dgae049","volume":"109","author":"S Gaillard","year":"2024","unstructured":"Gaillard S, Benichi S, Villa C, Jouinot A, Vatier C, Christin-Maitre S (2024) Prognostic impact of hypothalamic perforation in adult patients with craniopharyngioma: a cohort study. J Clin Endocrinol Metab 109(8):2083\u20132096. https:\/\/doi.org\/10.1210\/clinem\/dgae049","journal-title":"J Clin Endocrinol Metab"},{"issue":"4\u20135","key":"1760_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000094151","volume":"28","author":"PM Kochanek","year":"2006","unstructured":"Kochanek PM (2006) Pediatric Traumatic Brain Injury: Quo Vadis? Dev Neurosci 28(4\u20135):244\u2013255. https:\/\/doi.org\/10.1159\/000094151","journal-title":"Dev Neurosci"},{"issue":"5","key":"1760_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2014.03.003","volume":"28","author":"A Joly-Amado","year":"2014","unstructured":"Joly-Amado A, Cansell C, Denis RGP, Delbes AS, Castel J, Martinez S (2014) The hypothalamic arcuate nucleus and the control of peripheral substrates. Best Pract Res Clin Endocrinol Metab 28(5):725\u2013737. https:\/\/doi.org\/10.1016\/j.beem.2014.03.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1760_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fendo.2011.00081","volume":"2","author":"M Cohen","year":"2011","unstructured":"Cohen M, Guger S, Hamilton J (2011) Long term sequelae of pediatric craniopharyngioma: literature review and 20 years of experience. Front Endocrinol 2:81. https:\/\/doi.org\/10.3389\/fendo.2011.00081","journal-title":"Front Endocrinol"},{"issue":"6","key":"1760_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1055\/s-2003-45499","volume":"215","author":"HL M\u00fcller","year":"2003","unstructured":"M\u00fcller HL, Faldum A, Etavard-Gorris N, Gebhardt U, Oeverink R, Kolb R (2003) Functional Capacity, Obesity and Hypothalamic Involvement: Cross-Sectional Study on 212 Patients with Childhood Craniopharyngioma. Klin Padiatr 215(6):310\u2013314. https:\/\/doi.org\/10.1055\/s-2003-45499","journal-title":"Klin Padiatr"},{"key":"1760_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1114409","volume":"14","author":"M Lee","year":"2023","unstructured":"Lee M, Park MJ, Lee KH, Kim JH, Choi HJ, Kim YH (2023) Obesity mechanism after hypothalamic damage: cohort analysis of neuroimaging, psychological, cognitive, and clinical phenotyping data. Front Endocrinol 14:1114409. https:\/\/doi.org\/10.3389\/fendo.2023.1114409","journal-title":"Front Endocrinol"},{"issue":"11","key":"1760_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1515\/jpem-2024-0275","volume":"37","author":"M Papy","year":"2024","unstructured":"Papy M, Jacobs S, Rochtus A (2024) Endocrine sequelae after pediatric craniopharyngioma treatment: a single-center retrospective cohort study. J Pediatr Endocrinol Metab 37(11):954\u2013961. https:\/\/doi.org\/10.1515\/jpem-2024-0275","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"1760_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","volume":"40","author":"L van Iersel","year":"2019","unstructured":"van Iersel L, Brokke KE, Adan RAH, Bulthuis LCM, van den Akker ELT, van Santen HM (2019) Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. Endocr Rev 40(1):193\u2013235. https:\/\/doi.org\/10.1210\/er.2018-00017","journal-title":"Endocr Rev"},{"issue":"1","key":"1760_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11102-022-01294-0","volume":"26","author":"KN Rachmasari","year":"2023","unstructured":"Rachmasari KN, Strauss SB, Phillips CD, Lantos JE, An A, Cisse B (2023) Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas. Pituitary 26(1):105\u2013114. https:\/\/doi.org\/10.1007\/s11102-022-01294-0","journal-title":"Pituitary"},{"key":"1760_CR31","doi-asserted-by":"publisher","unstructured":"Beckhaus J, Eveslage M, Bison B, Friedrich C, M\u00fcller HL (2024) Impact of parental body mass index at diagnosis on obesity in survivors of pediatric craniopharyngioma. Endocr Connect 13(8). https:\/\/doi.org\/10.1530\/ec-24-0126","DOI":"10.1530\/ec-24-0126"},{"issue":"Supplement 2","key":"1760_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.15530","volume":"26","author":"CL Roth","year":"2024","unstructured":"Roth CL, McCormack SE (2024) Acquired hypothalamic obesity: A clinical overview and update. Diabetes Obes Metab 26(Supplement 2):34\u201345. https:\/\/doi.org\/10.1111\/dom.15530","journal-title":"Diabetes Obes Metab"},{"key":"1760_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fendo.2011.00060","volume":"2","author":"RH Lustig","year":"2011","unstructured":"Lustig RH (2011) Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Front Endocrinol 2:60. https:\/\/doi.org\/10.3389\/fendo.2011.00060","journal-title":"Front Endocrinol"},{"issue":"23","key":"1760_CR34","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402216rr","volume":"38","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Wu W, Liu F, Jin L, Jia Y, Qiao N (2024) Inflammatory mediator contributes to leptin resistance and obesity in craniopharyngioma. FASEB J 38(23):e70242. https:\/\/doi.org\/10.1096\/fj.202402216rr","journal-title":"FASEB J"},{"key":"1760_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fendo.2019.00140","volume":"10","author":"Y Benomar","year":"2019","unstructured":"Benomar Y, Taouis M (2019) Molecular mechanisms underlying obesity-induced hypothalamic inflammation and insulin resistance: pivotal role of resistin\/TLR4 pathways. Front Endocrinol 10:140. https:\/\/doi.org\/10.3389\/fendo.2019.00140","journal-title":"Front Endocrinol"},{"key":"1760_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/nu16162580","author":"HL Gao","year":"2024","unstructured":"Gao HL, Yang Y, Tian H, Xu SL, Li BW, Fu LY (2024) Puerarin alleviates blood pressure via inhibition of ROS\/TLR4\/NLRP3 inflammasome signaling pathway in the hypothalamic paraventricular nucleus of salt-induced prehypertensive rats. Nutrients. https:\/\/doi.org\/10.3390\/nu16162580","journal-title":"Nutrients"},{"issue":"3","key":"1760_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/jpet.123.002013","volume":"388","author":"P Thornton","year":"2024","unstructured":"Thornton P, Reader V, Digby Z, Smolak P, Lindsay N, Harrison D (2024) Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. J Pharmacol Exp Ther 388(3):813\u2013826. https:\/\/doi.org\/10.1124\/jpet.123.002013","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1760_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","volume":"68","author":"DT Meier","year":"2025","unstructured":"Meier DT, de Paula Souza J, Donath MY (2025) Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity. Diabetologia 68(1):3\u201316. https:\/\/doi.org\/10.1007\/s00125-024-06306-1","journal-title":"Diabetologia"},{"key":"1760_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310976","author":"SA Alenezi","year":"2023","unstructured":"Alenezi SA, Khan R, Snell L, Aboeldalyl S, Amer S (2023) The role of NLRP3 inflammasome in obesity and PCOS: a systematic review and meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241310976","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1760_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1530\/EJE-13-0832","volume":"170","author":"J Roemmler-Zehrer","year":"2014","unstructured":"Roemmler-Zehrer J, Geigenberger V, St\u00f6rmann S, Losa M, Crippa V, Otto B (2014) Food intake regulating hormones in adult craniopharyngioma patients. Eur J Endocrinol 170(4):627\u2013635. https:\/\/doi.org\/10.1530\/EJE-13-0832","journal-title":"Eur J Endocrinol"},{"issue":"11\u201312","key":"1760_CR41","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1515\/jpem-2015-0167","volume":"28","author":"I Bomer","year":"2015","unstructured":"Bomer I, Saure C, Caminiti C, Ramos JG, Zuccaro G, Brea M (2015) Comparison of energy expenditure, body composition, metabolic disorders, and energy intake between obese children with a history of craniopharyngioma and children with multifactorial obesity. J Pediatr Endocrinol Metab 28(11\u201312):1305\u20131312. https:\/\/doi.org\/10.1515\/jpem-2015-0167","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"1760_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1824-7288-37-38","volume":"37","author":"L Iughetti","year":"2011","unstructured":"Iughetti L, Bruzzi P (2011) Obesity and craniopharyngioma. Ital J Pediatr 37(1):38. https:\/\/doi.org\/10.1186\/1824-7288-37-38","journal-title":"Ital J Pediatr"},{"key":"1760_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09972-7","author":"D De Alcubierre","year":"2025","unstructured":"De Alcubierre D, Feola T, Puliani G, Ferrigno R, Amodeo ME, d\u2019Aniello F et al (2025) Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-025-09972-7","journal-title":"Rev Endocr Metab Disord"},{"issue":"Supplement1","key":"1760_CR44","doi-asserted-by":"publisher","first-page":"MON","DOI":"10.1210\/jendso\/bvaa046.1168","volume":"4","author":"D Duan","year":"2020","unstructured":"Duan D, Wehbeh L, Mukherjee D, Hamrahian AH, Ahima RS, Maruthur NM (2020) MON-276 Post-Surgical Metabolic Outcomes in Adult-Onset Craniopharyngioma: A Single Pituitary Center Experience. J Endocr Soc 4(Supplement1):MON\u2013276. https:\/\/doi.org\/10.1210\/jendso\/bvaa046.1168","journal-title":"J Endocr Soc"},{"issue":"6","key":"1760_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/metabo14060338","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Feng Y, Wu D, Xie Y, Wu G, Wu W (2024) Serum Metabolomic and Lipidomic Profiling Reveals the Signature for Postoperative Obesity among Adult-Onset Craniopharyngioma. Metabolites 14(6):338. https:\/\/doi.org\/10.3390\/metabo14060338","journal-title":"Metabolites"},{"issue":"1","key":"1760_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/jc.2003-030442","volume":"89","author":"S Srinivasan","year":"2004","unstructured":"Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT (2004) Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 89(1):81\u201386. https:\/\/doi.org\/10.1210\/jc.2003-030442","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1760_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.6065\/apem.2017.22.3.189","volume":"22","author":"SY Jung","year":"2017","unstructured":"Jung SY, Lee YJ, Lee HJ, Lee YA, Moon JS, Ko JS (2017) Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab 22(3):189\u2013196. https:\/\/doi.org\/10.6065\/apem.2017.22.3.189","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"3","key":"1760_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/eje-15-0422","volume":"173","author":"A Hoffmann","year":"2015","unstructured":"Hoffmann A, Bootsveld K, Gebhardt U, Daubenb\u00fcchel AMM, Sterkenburg AS, M\u00fcller HL (2015) Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 173(3):389\u2013397. https:\/\/doi.org\/10.1530\/eje-15-0422","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1760_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12020-022-03134-4","volume":"78","author":"P Dogra","year":"2022","unstructured":"Dogra P, Bedatsova L, Van Gompel JJ, Giannini C, Donegan DM, Erickson D (2022) Long-term outcomes in patients with adult-onset craniopharyngioma. Endocrine 78(1):123\u2013134. https:\/\/doi.org\/10.1007\/s12020-022-03134-4","journal-title":"Endocrine"},{"key":"1760_CR50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/dmso.s504968","volume":"18","author":"L Chen","year":"2025","unstructured":"Chen L, Wu W, Ye H (2025) Risk Factors for MAFLD and Advanced Liver Fibrosis in Adult-Onset Craniopharyngioma Patients: A Cross-Sectional Study. Diabetes Metab Syndr Obes 18:859\u2013871. https:\/\/doi.org\/10.2147\/dmso.s504968","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"1760_CR51","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.clnu.2024.05.028","volume":"43","author":"IMAA Van Roessel","year":"2024","unstructured":"Van Roessel IMAA, Van Den Brink M, Dekker J, Ruitenburg-van Essen BG, Tissing WJE, van Santen HM (2024) Feasibility, safety, and efficacy of dietary or lifestyle interventions for hypothalamic obesity: a systematic review. Clin Nutr 43(8):1798\u20131811. https:\/\/doi.org\/10.1016\/j.clnu.2024.05.028","journal-title":"Clin Nutr"},{"issue":"4","key":"1760_CR52","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1210\/clinem\/dgaa985","volume":"106","author":"D Duan","year":"2021","unstructured":"Duan D, Wehbeh L, Mukherjee D, Hamrahian AH, Rodriguez FJ, Gujar S (2021) Preoperative BMI Predicts Postoperative Weight Gain in Adult-onset Craniopharyngioma. J Clin Endocrinol Metab 106(4):1603\u20131617. https:\/\/doi.org\/10.1210\/clinem\/dgaa985","journal-title":"J Clin Endocrinol Metab"},{"key":"1760_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/20552076221102774","volume":"8","author":"CA Carpenter","year":"2022","unstructured":"Carpenter CA, Ugwoaba UA, Cardel MI, Ross KM (2022) Using self-monitoring technology for nutritional counseling and weight management. Digit Health 8:20552076221102774. https:\/\/doi.org\/10.1177\/20552076221102774","journal-title":"Digit Health"},{"issue":"6","key":"1760_CR54","first-page":"1249","volume":"67","author":"KJ McInnis","year":"2003","unstructured":"McInnis KJ, Franklin BA, Rippe JM (2003) Counseling for Physical Activity in Overweight and Obese Patients. Am Fam Physician 67(6):1249\u20131256","journal-title":"Am Fam Physician"},{"issue":"4","key":"1760_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00520-025-09361-5","volume":"33","author":"IMAA Van Roessel","year":"2025","unstructured":"Van Roessel IMAA, Van Schaik J, Kleinlugtenbelt LB, van Duijn SN, Burghard M, Takken T (2025) Physical activity, health-related fitness, and physical performance in children with acquired hypothalamic dysfunction. Support Care Cancer 33(4):295. https:\/\/doi.org\/10.1007\/s00520-025-09361-5","journal-title":"Support Care Cancer"},{"issue":"Supplement 1","key":"1760_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.05362","volume":"34","author":"SJ Lindsey","year":"2020","unstructured":"Lindsey SJ, Mounger DK, Fraley SK, Hillard KJ, Zahner MR (2020) GLP-1 Agonist Liraglutide Activates Metabolic- and Cardiovascular-Related Hypothalamic Neurons and Augments Reflex Sympathetic Activity in the Rat. FASEB J 34(Supplement 1):1. https:\/\/doi.org\/10.1096\/fasebj.2020.34.s1.05362","journal-title":"FASEB J"},{"issue":"6707","key":"1760_CR57","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","volume":"385","author":"KS Kim","year":"2024","unstructured":"Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH (2024) GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science 385(6707):438\u2013446. https:\/\/doi.org\/10.1126\/science.adj2537","journal-title":"Science"},{"issue":"5","key":"1760_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11102-024-01426-8","volume":"27","author":"E Gjersdal","year":"2024","unstructured":"Gjersdal E, Larsen LB, Ettrup KS, Vestergaard P, Nielsen EH, Karmisholt JS (2024) Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma. Pituitary 27(5):723\u2013730. https:\/\/doi.org\/10.1007\/s11102-024-01426-8","journal-title":"Pituitary"},{"issue":"4","key":"1760_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ejendo\/lvae024","volume":"190","author":"B Gatta-Cherifi","year":"2024","unstructured":"Gatta-Cherifi B, Mohammedi K, Cariou T, Poitou C, Touraine P, Raverot G (2024) Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol 190(4):257\u2013265. https:\/\/doi.org\/10.1093\/ejendo\/lvae024","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1760_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12642","volume":"14","author":"VWW Ng","year":"2024","unstructured":"Ng VWW, Gerard G, Koh JJK, Loke KY, Lee YS, Ng NBH (2024) The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity: a systematic review. Clin Obes 14(3):e12642. https:\/\/doi.org\/10.1111\/cob.12642","journal-title":"Clin Obes"},{"issue":"3","key":"1760_CR61","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","volume":"46","author":"AH Shoemaker","year":"2022","unstructured":"Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C (2022) Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int J Obes (Lond) 46(3):623\u2013629. https:\/\/doi.org\/10.1038\/s41366-021-01043-6","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"1760_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/417949","volume":"2011","author":"JK Hamilton","year":"2011","unstructured":"Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D (2011) Hypothalamic Obesity following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin Therapy. Int J Pediatr Endocrinol 2011(1):1\u20137. https:\/\/doi.org\/10.1155\/2011\/417949","journal-title":"Int J Pediatr Endocrinol"},{"key":"1760_CR63","doi-asserted-by":"publisher","first-page":"1307889","DOI":"10.3389\/fendo.2024.1307889","volume":"14","author":"HM van Santen","year":"2024","unstructured":"van Santen HM, Denzer C, M\u00fcller HL (2024) Could setmelanotide be the game-changer for acquired hypothalamic obesity? Front Endocrinol 14:1307889. https:\/\/doi.org\/10.3389\/fendo.2024.1307889","journal-title":"Front Endocrinol"},{"issue":"1","key":"1760_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.aed.2025.03.004","volume":"12","author":"S Brijmohan","year":"2025","unstructured":"Brijmohan S, Mullally JA (2025) Successful Treatment of Hypothalamic Obesity with Tirzepatide. AACE Endocrinol Diabetes 12(1):30\u201333. https:\/\/doi.org\/10.1016\/j.aed.2025.03.004","journal-title":"AACE Endocrinol Diabetes"},{"issue":"3","key":"1760_CR65","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/dom.16106","volume":"27","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhu H, Gong F (2025) Why does GLP-1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? Diabetes Obes Metab 27(3):1079\u20131095. https:\/\/doi.org\/10.1111\/dom.16106","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1760_CR66","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/nejmoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R (2023) Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 389(10):877\u2013888. https:\/\/doi.org\/10.1056\/nejmoa2302392","journal-title":"N Engl J Med"},{"issue":"Supplement_3","key":"1760_CR67","doi-asserted-by":"publisher","first-page":"iii423","DOI":"10.1093\/neuonc\/noaa222.631","volume":"22","author":"M Hemenway","year":"2020","unstructured":"Hemenway M, Dorris K, Rydin A, Inge T, Kelsey M, Hankinson T (2020) NURS-12. Making survivors healthier: a multidisciplinary approach to hypothalamic obesity. Neuro Oncol 22(Supplement_3):iii423. https:\/\/doi.org\/10.1093\/neuonc\/noaa222.631","journal-title":"Neuro Oncol"},{"issue":"11","key":"1760_CR68","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1016\/j.soard.2024.05.009","volume":"34","author":"M De Luca","year":"2024","unstructured":"De Luca M, Shikora S, Eisenberg D, Angrisani L, Parmar C, Alqahtani A (2024) Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO\/ASMBS). Obes Surg 34(11):3963\u20134096. https:\/\/doi.org\/10.1016\/j.soard.2024.05.009","journal-title":"Obes Surg"},{"issue":"3","key":"1760_CR69","doi-asserted-by":"publisher","first-page":"221","DOI":"10.18544\/ep-01.16.03.1677","volume":"16","author":"E Moszczy\u0144ska","year":"2017","unstructured":"Moszczy\u0144ska E, Szalecki M, Pasternak-Pietrzak K (2017) Treatment methods of craniopharyngioma and its complications with a particular emphasis on obesity. Pediatr Endocrinol 16(3):221\u2013234. https:\/\/doi.org\/10.18544\/ep-01.16.03.1677","journal-title":"Pediatr Endocrinol"},{"issue":"4","key":"1760_CR70","first-page":"348","volume":"14","author":"S Stolbova","year":"2017","unstructured":"Stolbova S, Benes M, Petruzelkova L, Lebl J, Kolouskova S (2017) For Debate: Should Bariatric Surgery be Performed in Children and Adolescents with Hypothalamic Obesity? Pediatr Endocrinol Rev 14(4):348\u2013352","journal-title":"Pediatr Endocrinol Rev"},{"key":"1760_CR71","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab518","author":"SS van Santen","year":"2021","unstructured":"van Santen SS, Wolf P, Kremenevski N, Boguszewski CL, Beiglb\u00f6ck H, Fiocco M (2021) Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgab518","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1760_CR72","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","volume":"12","author":"CL Roth","year":"2024","unstructured":"Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G (2024) Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol 12(6):380\u2013389. https:\/\/doi.org\/10.1016\/S2213-8587(24)00087-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1760_CR73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1037\/hea0001257","volume":"42","author":"J Reiter-Purtill","year":"2023","unstructured":"Reiter-Purtill J, Decker KM, Jenkins TM, Zeller MH (2023) Self-worth and developmental outcomes in young adults after pediatric bariatric surgery. Health Psychol 42(2):92\u2013102. https:\/\/doi.org\/10.1037\/hea0001257","journal-title":"Health Psychol"},{"issue":"7","key":"1760_CR74","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.soard.2018.03.019","volume":"14","author":"JSA Pratt","year":"2018","unstructured":"Pratt JSA, Browne A, Browne NT, Bruzoni M, Cohen M, Desai A (2018) ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 14(7):882\u2013901. https:\/\/doi.org\/10.1016\/j.soard.2018.03.019","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"1760_CR75","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1210\/jc.2017-01542","volume":"103","author":"KCJ Yuen","year":"2018","unstructured":"Yuen KCJ, Mattsson AF, Burman P, Erfurth EM, Camacho-Hubner C, Fox JL (2018) Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement. J Clin Endocrinol Metab 103(2):768\u2013777. https:\/\/doi.org\/10.1210\/jc.2017-01542","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1760_CR76","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/oby.23447","volume":"30","author":"J Wu","year":"2022","unstructured":"Wu J, Fu J, Huang ZJ, Xie SH, Tang B, Wu X (2022) Postoperative hypothalamic damage predicts postoperative weight gain in patients with adult-onset craniopharyngioma. Obes (Silver Spring) 30(7):1357\u20131369. https:\/\/doi.org\/10.1002\/oby.23447","journal-title":"Obes (Silver Spring)"},{"issue":"2","key":"1760_CR77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.6065\/apem.2244046.023","volume":"28","author":"SH Park","year":"2022","unstructured":"Park SH, Lee YJ, Cheon JE, Shin CH, Jung HW, Lee YA (2022) The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab 28(2):107\u2013115. https:\/\/doi.org\/10.6065\/apem.2244046.023","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"1","key":"1760_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1297\/cpe.16.1","volume":"16","author":"M Adachi","year":"2007","unstructured":"Adachi M, Tsuchiya T, Muroya K, Asakura Y, Sekido K, Sato H (2007) Prevalence of Obesity, Hyperlipemia and Insulin Resistance in Children with Suprasellar Brain Tumors. Clin Pediatr Endocrinol 16(1):1\u20139. https:\/\/doi.org\/10.1297\/cpe.16.1","journal-title":"Clin Pediatr Endocrinol"},{"issue":"2","key":"1760_CR79","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000496564","volume":"91","author":"MJ Abuzzahab","year":"2019","unstructured":"Abuzzahab MJ, Roth CL, Shoemaker AH (2019) Hypothalamic Obesity: Prologue and Promise. Horm Res Paediatr 91(2):128\u2013136. https:\/\/doi.org\/10.1159\/000496564","journal-title":"Horm Res Paediatr"},{"key":"1760_CR80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fendo.2011.00049","volume":"2","author":"CL Roth","year":"2011","unstructured":"Roth CL (2011) Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Front Endocrinol 2:49. https:\/\/doi.org\/10.3389\/fendo.2011.00049","journal-title":"Front Endocrinol"},{"issue":"1","key":"1760_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/eje-17-0387","volume":"178","author":"M Wijnen","year":"2018","unstructured":"Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, Hammarstrand C, Janssen JAMJL, van der Lely AJ (2018) The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. Eur J Endocrinol 178(1):11\u201322. https:\/\/doi.org\/10.1530\/eje-17-0387","journal-title":"Eur J Endocrinol"},{"key":"1760_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.783737","volume":"13","author":"E Scarano","year":"2022","unstructured":"Scarano E, Solari D, Riccio E, Arianna R, Somma T, Cavallo LM et al (2022) Craniopharyngioma and metabolic syndrome: a 5-year follow-up single-center experience. Front Neurol 13:783737. https:\/\/doi.org\/10.3389\/fneur.2022.783737","journal-title":"Front Neurol"},{"issue":"1","key":"1760_CR83","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5546\/aap.2017.eng.43","volume":"115","author":"C Caminiti","year":"2017","unstructured":"Caminiti C, Saure C, Bomer I, Brea M, Gonzalez Ramos J (2017) Nutritional assessment of a population with a history of childhood craniopharyngioma seen at Hospital \u2018Prof. Dr. Juan P. Garrahan\u2019. Arch Argent Pediatr 115(1):43\u201349. https:\/\/doi.org\/10.5546\/aap.2017.eng.43","journal-title":"Arch Argent Pediatr"},{"issue":"5","key":"1760_CR84","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00431-020-03915-x","volume":"180","author":"P Sowithayasakul","year":"2021","unstructured":"Sowithayasakul P, Buschmann LK, Boekhoff S, M\u00fcller HL (2021) Cardiac remodeling in patients with childhood-onset craniopharyngioma: results of HIT-Endo and KRANIOPHARYNGEOM 2000\/2007. Eur J Pediatr 180(5):1593\u20131602. https:\/\/doi.org\/10.1007\/s00431-020-03915-x","journal-title":"Eur J Pediatr"},{"issue":"5","key":"1760_CR85","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s11695-015-1977-z","volume":"26","author":"M Bretault","year":"2016","unstructured":"Bretault M, Laroche S, Lacorte JM, Barsamian C, Polak M, Raffin-Sanson ML (2016) Postprandial GLP-1 Secretion After Bariatric Surgery in Three Cases of Severe Obesity Related to Craniopharyngiomas. Obes Surg 26(5):1133\u20131137. https:\/\/doi.org\/10.1007\/s11695-015-1977-z","journal-title":"Obes Surg"},{"issue":"7","key":"1760_CR86","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep4.1935","volume":"6","author":"M Noureddin","year":"2022","unstructured":"Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E (2022) Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning. Hepatol Commun 6(7):1537. https:\/\/doi.org\/10.1002\/hep4.1935","journal-title":"Hepatol Commun"},{"issue":"5","key":"1760_CR87","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/pon.5862","volume":"31","author":"KL Klages","year":"2022","unstructured":"Klages KL, Berlin KS, Cook JL, Merchant TE, Wise MS, Mandrell BN (2022) Health-related quality of life, obesity, fragmented sleep, fatigue, and psychosocial problems among youth with craniopharyngioma. Psychooncology 31(5):779\u2013787. https:\/\/doi.org\/10.1002\/pon.5862","journal-title":"Psychooncology"},{"issue":"4","key":"1760_CR88","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3171\/ped.2005.103.4.0302","volume":"103","author":"SA Sands","year":"2005","unstructured":"Sands SA, Milner JS, Goldberg J, Mukhi V, Moliterno JA, Maxfield C (2005) Quality of life and behavioral follow-up study of pediatric survivors of craniopharyngioma. J Neurosurg Pediatr 103(4):302\u2013311. https:\/\/doi.org\/10.3171\/ped.2005.103.4.0302","journal-title":"J Neurosurg Pediatr"},{"issue":"4","key":"1760_CR89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1017\/s0012162204000374","volume":"46","author":"A Poretti","year":"2004","unstructured":"Poretti A, Grotzer MA, Ribi K, Boltshauser E (2004) Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol 46(4):220\u2013229. https:\/\/doi.org\/10.1017\/s0012162204000374","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"1760_CR90","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00381-005-1205-6","volume":"21","author":"A Pierre-Kahn","year":"2005","unstructured":"Pierre-Kahn A, Recassens C, Pinto G, Thalassinos C, Chokron S, Soubervielle JC (2005) Social and psycho-intellectual outcome following radical removal of craniopharyngiomas in childhood. Childs Nerv Syst 21(8):817\u2013824. https:\/\/doi.org\/10.1007\/s00381-005-1205-6","journal-title":"Childs Nerv Syst"},{"issue":"11","key":"1760_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076562","volume":"8","author":"G Zada","year":"2013","unstructured":"Zada G, Kintz N, Pulido M, Amezcua L (2013) Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review. PLoS One 8(11):e76562. https:\/\/doi.org\/10.1371\/journal.pone.0076562","journal-title":"PLoS One"},{"issue":"5","key":"1760_CR92","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad037","volume":"7","author":"SE McCormack","year":"2023","unstructured":"McCormack SE, Wang Z, Wade KL, Dedio A, Cilenti N, Crowley J (2023) A pilot randomized clinical trial of intranasal oxytocin to promote weight loss in individuals with hypothalamic obesity. J Endocr Soc 7(5):bvad037. https:\/\/doi.org\/10.1210\/jendso\/bvad037","journal-title":"J Endocr Soc"},{"issue":"2","key":"1760_CR93","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1210\/jc.2017-02080","volume":"103","author":"EA Hsu","year":"2018","unstructured":"Hsu EA, Miller JL, Perez FA, Roth CL (2018) Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. J Clin Endocrinol Metab 103(2):370\u2013375. https:\/\/doi.org\/10.1210\/jc.2017-02080","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"1760_CR94","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1073\/pnas.0706473105","volume":"105","author":"JD Roth","year":"2008","unstructured":"Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105(20):7257\u20137262. https:\/\/doi.org\/10.1073\/pnas.0706473105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1760_CR95","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","volume":"108","author":"JL Miller","year":"2023","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS (2023) Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol Metab 108(7):1676\u20131685","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1760_CR96","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/biomedicines13051016","volume":"13","author":"HL M\u00fcller","year":"2025","unstructured":"M\u00fcller HL (2025) Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma: A Narrative Review. Biomedicines 13(5):1016. https:\/\/doi.org\/10.3390\/biomedicines13051016","journal-title":"Biomedicines"},{"issue":"1","key":"1760_CR97","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000530863","volume":"97","author":"EC Hinton","year":"2023","unstructured":"Hinton EC, Lithander FE, Elsworth RL, Hawton K, Narayan K, Szymkowiak S (2023) Evaluating Eating Behaviour, Energy Homeostasis, and Obesity in Childhood-Onset Craniopharyngioma: A Feasibility Study. Horm Res Paediatr 97(1):80\u201393. https:\/\/doi.org\/10.1159\/000530863","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"1760_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/cen.15133","volume":"102","author":"G Torbahn","year":"2025","unstructured":"Torbahn G, Lischka J, Brown T, Ells LJ, Kelly AS, Wabitsch M (2025) Anti-obesity medication in the management of children and adolescents with obesity: recent developments and research gaps. Clin Endocrinol (Oxf) 102(1):51\u201361. https:\/\/doi.org\/10.1111\/cen.15133","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1760_CR99","doi-asserted-by":"publisher","unstructured":"White PC, Sen GP, Tang F, Chen J, Lin-Su K, Matos D (2024) Natural History Of Classic Congenital Adrenal Hyperplasia: Results From Pediatric And Adult Patients In The CAHtalog Registry. J Endocr Soc 8(Supplement1). https:\/\/doi.org\/10.1210\/jendso\/bvae163.244.\u00a0","DOI":"10.1210\/jendso\/bvae163.244"},{"key":"1760_CR100","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-04987-1","author":"HL M\u00fcller","year":"2025","unstructured":"M\u00fcller HL (2025) Long-term quality of life and hypothalamic dysfunction after craniopharyngioma. J Neuro Oncol. https:\/\/doi.org\/10.1007\/s11060-025-04987-1","journal-title":"J Neuro Oncol"},{"key":"1760_CR101","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2024.2024-1-3","author":"Z \u015e\u0131klar","year":"2024","unstructured":"\u015e\u0131klar Z, \u00d6zsu E, \u00c7etin SK, \u00d6zen S, \u00c7izmecio\u011flu-Jones F, Balk\u0131 HG et al (2024) Comprehensive insights into pediatric craniopharyngioma: endocrine and metabolic profiles, treatment challenges, and long-term outcomes from a Multicenter Study. J Clin Res Pediatr Endocrinol. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2024.2024-1-3","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"6","key":"1760_CR102","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1210\/jc.2012-3928","volume":"98","author":"E Elowe-Gruau","year":"2013","unstructured":"Elowe-Gruau E, Beltrand J, Brauner R, Pinto G, Samara-Boustani D, Thalassinos C (2013) Childhood Craniopharyngioma: Hypothalamus-Sparing Surgery Decreases the Risk of Obesity. J Clin Endocrinol Metab 98(6):2376\u20132382. https:\/\/doi.org\/10.1210\/jc.2012-3928","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1760_CR103","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3171\/2024.7.peds2429","volume":"34","author":"T Brooks","year":"2024","unstructured":"Brooks T, Gao D, Dorris K, Boone K, Mirsky DM, Staulcup S (2024) Does pre-irradiation gross tumor volume predict the risk of progression after radiation therapy in pediatric patients with adamantinomatous craniopharyngioma? J Neurosurg Pediatr 34(6):642\u2013648. https:\/\/doi.org\/10.3171\/2024.7.peds2429","journal-title":"J Neurosurg Pediatr"},{"issue":"6","key":"1760_CR104","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE (2003) Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol Metab 88(6):2586\u20132592. https:\/\/doi.org\/10.1210\/jc.2002-030003","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_4","key":"1760_CR105","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1093\/neuonc\/noae064.589","volume":"26","author":"I van Roessel","year":"2024","unstructured":"van Roessel I, van den Brink M, Dekker J, van Essen BGR, Tissing WJE, van Santen HM (2024) QOL-01. Feasibility and efficacy of dietary and lifestyle interventions for hypothalamic obesity during childhood: a systematic review. Neuro Oncol 26(Supplement_4):0. https:\/\/doi.org\/10.1093\/neuonc\/noae064.589","journal-title":"Neuro Oncol"},{"issue":"1","key":"1760_CR106","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","volume":"12","author":"C Denzer","year":"2019","unstructured":"Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M (2019) Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series. Obes Facts 12(1):91\u2013102. https:\/\/doi.org\/10.1159\/000495851","journal-title":"Obes Facts"},{"issue":"3","key":"1760_CR107","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/children9030411","volume":"9","author":"M Otth","year":"2022","unstructured":"Otth M, Michel G, Gerber NU, Guerreiro St\u00fccklin AS, von Bueren AO, Scheinemann K (2022) Educational Attainment and Employment Outcome of Survivors of Pediatric CNS Tumors in Switzerland: A Report from the Swiss Childhood Cancer Survivor Study. Child (Basel) 9(3):411. https:\/\/doi.org\/10.3390\/children9030411","journal-title":"Child (Basel)"},{"key":"1760_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.717544","volume":"12","author":"X Lu","year":"2021","unstructured":"Lu X, Huang L, Huang Z, Feng D, Clark RJ, Chen C (2021) LEAP-2: an emerging endogenous ghrelin receptor antagonist in the pathophysiology of obesity. Front Endocrinol 12:717544. https:\/\/doi.org\/10.3389\/fendo.2021.717544","journal-title":"Front Endocrinol"},{"issue":"3","key":"1760_CR109","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4149\/endo_2014_03_126","volume":"48","author":"S Abdel-Hakim","year":"2014","unstructured":"Abdel-Hakim S, Ibrahim M, Ibrahim H, Ibrahim M (2014) The effect of ghrelin antagonist (D-Lys3) GHRP-6 on ovariectomy-induced obesity in adult female albino rats. Endocr Regul 48(3):126\u2013134. https:\/\/doi.org\/10.4149\/endo_2014_03_126","journal-title":"Endocr Regul"},{"key":"1760_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216897","author":"AM D\u0105browska","year":"2023","unstructured":"D\u0105browska AM, Dudka J (2023) Mirabegron, a selective \u03b23-adrenergic receptor agonist, as a potential anti-obesity drug. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12216897","journal-title":"J Clin Med"},{"issue":"35","key":"1760_CR111","doi-asserted-by":"publisher","first-page":"eaaz9890","DOI":"10.1126\/sciadv.aaz9890","volume":"6","author":"CA Gilroy","year":"2020","unstructured":"Gilroy CA, Capozzi ME, Varanko AK, Tong J, D\u2019Alessio DA, Campbell JE (2020) Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci Adv 6(35):eaaz9890. https:\/\/doi.org\/10.1126\/sciadv.aaz9890","journal-title":"Sci Adv"},{"key":"1760_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103202","author":"Q Pan","year":"2021","unstructured":"Pan Q, Lin S, Li Y, Liu L, Li X, Gao X et al (2021) A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103202","journal-title":"EBioMedicine"},{"issue":"6","key":"1760_CR113","doi-asserted-by":"publisher","first-page":"R1032","DOI":"10.1152\/ajpregu.00326.2016","volume":"311","author":"MD Johnson","year":"2016","unstructured":"Johnson MD, Bouret SG, Dunn-Meynell AA, Boyle CN, Lutz TA, Levin BE (2016) Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat. Am J Physiol Regul Integr Comp Physiol 311(6):R1032\u2013R1044. https:\/\/doi.org\/10.1152\/ajpregu.00326.2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"1760_CR114","doi-asserted-by":"publisher","first-page":"R355","DOI":"10.1152\/ajpregu.00462.2015","volume":"310","author":"AA Dunn-Meynell","year":"2016","unstructured":"Dunn-Meynell AA, Le Foll C, Johnson MD, Lutz TA, Hayes MR, Levin BE (2016) Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 310(4):R355\u2013R365. https:\/\/doi.org\/10.1152\/ajpregu.00462.2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"1760_CR115","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7150\/thno.36572","volume":"10","author":"V Osinski","year":"2020","unstructured":"Osinski V, Bauknight DK, Dasa SSK, Harms MJ, Kroon T, Marshall MA (2020) In vivo liposomal delivery of PPAR\u03b1\/\u03b3 dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects. Theranostics 10(2):585. https:\/\/doi.org\/10.7150\/thno.36572","journal-title":"Theranostics"},{"issue":"Supplement_1","key":"1760_CR116","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.2406","volume":"8","author":"CX Zhang","year":"2024","unstructured":"Zhang CX, Lieu C, He W, Belsham DD (2024) OR01-01 Novel anti-obesity phytohormone promotes cellular insulin sensitivity in hypothalamic neurons. J Endocr Soc 8(Supplement_1):bvae163.2406. https:\/\/doi.org\/10.1210\/jendso\/bvae163.2406","journal-title":"J Endocr Soc"},{"issue":"7","key":"1760_CR117","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/npp.2010.16","volume":"35","author":"AMD Axel","year":"2010","unstructured":"Axel AMD, Mikkelsen JD, Hansen HH (2010) Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of \u03b11 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35(7):1464\u20131476. https:\/\/doi.org\/10.1038\/npp.2010.16","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1760_CR118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.03.026","volume":"636","author":"HH Hansen","year":"2010","unstructured":"Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AMD, Raben A (2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. Eur J Pharmacol 636(1):88\u201395. https:\/\/doi.org\/10.1016\/j.ejphar.2010.03.026","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1760_CR119","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/eje-21-0972","volume":"186","author":"K Huynh","year":"2022","unstructured":"Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S (2022) Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol 186(6):687\u2013700. https:\/\/doi.org\/10.1530\/eje-21-0972","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1760_CR120","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T (2012) Controlled-Release Phentermine\/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obes (Silver Spring) 20(2):330\u2013342. https:\/\/doi.org\/10.1038\/oby.2011.330","journal-title":"Obes (Silver Spring)"},{"issue":"4","key":"1760_CR121","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/dom.13910","volume":"22","author":"DS Hsia","year":"2020","unstructured":"Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W (2020) A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine\/topiramate in adolescents with obesity. Diabetes Obes Metab 22(4):480\u2013491. https:\/\/doi.org\/10.1111\/dom.13910","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1760_CR122","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1530\/ec-19-0074","volume":"8","author":"A Bogusz","year":"2019","unstructured":"Bogusz A, Boekhoff S, Warmuth-Metz M, Calaminus G, Eveslage M, M\u00fcller HL (2019) Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect 8(5):481\u2013492. https:\/\/doi.org\/10.1530\/ec-19-0074","journal-title":"Endocr Connect"},{"issue":"4","key":"1760_CR123","doi-asserted-by":"publisher","first-page":"356","DOI":"10.23736\/s0391-1977.17.02615-3","volume":"42","author":"HL M\u00fcller","year":"2017","unstructured":"M\u00fcller HL (2017) Diagnosis, treatment, clinical course, and prognosis of childhood-onset craniopharyngioma patients. Minerva Endocrinol 42(4):356\u2013375. https:\/\/doi.org\/10.23736\/s0391-1977.17.02615-3","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"1760_CR124","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/2023.10.peds23293","volume":"33","author":"M Caklili","year":"2024","unstructured":"Caklili M, Uzuner A, Yilmaz E, Duman Ozturk S, Cizmecioglu Jones FM, Balci S (2024) Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study. J Neurosurg Pediatr 33(3):223\u2013235. https:\/\/doi.org\/10.3171\/2023.10.peds23293","journal-title":"J Neurosurg Pediatr"},{"issue":"2","key":"1760_CR125","doi-asserted-by":"publisher","DOI":"10.3171\/2020.4.focusvid.19983","volume":"2","author":"A Mohyeldin","year":"2020","unstructured":"Mohyeldin A, Hwang P, Grant GA, Fernandez-Miranda JC (2020) Endoscopic endonasal surgery for giant pediatric craniopharyngioma. Neurosurg Focus Video 2(2):V8. https:\/\/doi.org\/10.3171\/2020.4.focusvid.19983","journal-title":"Neurosurg Focus Video"},{"issue":"1","key":"1760_CR126","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00701-025-06449-z","volume":"167","author":"C Biswas","year":"2025","unstructured":"Biswas C, Abouammo MD, Pasquini L, Mansur G, Alsavaf MB, Wu KC (2025) Use of intraoperative ultrasound in differentiating adamantinomatous versus papillary craniopharyngiomas and guiding resection through the endoscopic endonasal route. Acta Neurochir (Wien) 167(1):42. https:\/\/doi.org\/10.1007\/s00701-025-06449-z","journal-title":"Acta Neurochir (Wien)"},{"key":"1760_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1073736","volume":"10","author":"G Finger","year":"2023","unstructured":"Finger G, Wu KC, Godil SS, Carrau RL, Hardesty D, Prevedello DM (2023) Ultrasound-guided endoscopic endonasal resection of sellar and suprasellar craniopharyngiomas. Front Surg 10:1073736. https:\/\/doi.org\/10.3389\/fsurg.2023.1073736","journal-title":"Front Surg"},{"issue":"1","key":"1760_CR128","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1227\/ons.0000000000001067","volume":"27","author":"A Shen","year":"2024","unstructured":"Shen A, Yu Y, Lyu L, Jiang S, Zhou D, Xu J et al (2024) One-and-a-Half interdural transcavernous pituitary transposition\/rotation for protection of hypophyseal portal system in adult peripheral retroinfundibular craniopharyngioma. Oper Neurosurg (Hagerstown) 27(1):72\u201385. https:\/\/doi.org\/10.1227\/ons.0000000000001067","journal-title":"Oper Neurosurg (Hagerstown)"},{"key":"1760_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1180993","volume":"13","author":"C Friedrich","year":"2023","unstructured":"Friedrich C, Boekhoff S, Bischoff M, Beckhaus J, Sowithayasakul P, Calaminus G et al (2023) Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients: results of KRANIOPHARYNGEOM 2007. Front Oncol 13:1180993. https:\/\/doi.org\/10.3389\/fonc.2023.1180993","journal-title":"Front Oncol"},{"issue":"Supplement2","key":"1760_CR130","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3171\/2014.8.gks141411","volume":"121","author":"CC Lee","year":"2014","unstructured":"Lee CC, Yang HC, Chen CJ, Hung YC, Wu HM, Shiau CY (2014) Gamma Knife surgery for craniopharyngioma: report on a 20-year experience. J Neurosurg 121(Supplement2):167\u2013178. https:\/\/doi.org\/10.3171\/2014.8.gks141411","journal-title":"J Neurosurg"},{"key":"1760_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F, Jacquesson T, Manet R, Vasiljevic A, Lasolle H, Ducray F et al (2022) Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm. Front Endocrinol 13:882381. https:\/\/doi.org\/10.3389\/fendo.2022.882381","journal-title":"Front Endocrinol"},{"issue":"2","key":"1760_CR132","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ejendo\/lvae091","volume":"191","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, Briet C, Almairac F (2024) BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. Eur J Endocrinol 191(2):251\u2013261. https:\/\/doi.org\/10.1093\/ejendo\/lvae091","journal-title":"Eur J Endocrinol"},{"key":"1760_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051045","author":"S Giuliani","year":"2024","unstructured":"Giuliani S, Paraboschi I, McNair A, Smith M, Rankin KS, Elson DS (2024) Monoclonal antibodies for targeted fluorescence-guided surgery: a review of applicability across multiple solid tumors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16051045","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1760_CR134","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad049","volume":"7","author":"PA Sutton","year":"2023","unstructured":"Sutton PA, van Dam MA, Cahill RA, Mieog S, Polom K, Vahrmeijer AL (2023) Fluorescence-guided surgery: comprehensive review. BJS Open 7(3):zrad049. https:\/\/doi.org\/10.1093\/bjsopen\/zrad049","journal-title":"BJS Open"},{"issue":"4","key":"1760_CR135","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3171\/2023.7.jns231170","volume":"140","author":"T Picart","year":"2024","unstructured":"Picart T, Pallud J, Berthiller J, Dumot C, Berhouma M, Ducray F (2024) Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study. J Neurosurg 140(4):987\u20131000. https:\/\/doi.org\/10.3171\/2023.7.jns231170","journal-title":"J Neurosurg"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01760-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:11:52Z","timestamp":1793455912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01760-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1760"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01760-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a scoping review of previously published literature and did not involve human participants, animal subjects, or identifiable patient data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative artificial intelligence was used to assist with language editing, formatting, and citation consistency checking during the preparation of this manuscript. All scientific content and citations were reviewed and verified by the authors, who take full responsibility for the integrity of the work.","order":4,"name":"Ethics","label":"Generative artificial intelligence use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"161"}}